NOVALIQ ANNOUNCES POSITIVE TOPLINE RESULTS FOR SECOND PHASE 3 TRIAL (ESSENCE-2) OF CYCLASOL® IN DRY EYE DISEASE
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced key results of the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational drug CyclASol® for the treatment of dry eye disease (DED).